Results 111 to 120 of about 2,566,374 (138)

Implementing treat-to-target urate-lowering therapy during hospitalizations for gout flares. [PDF]

Rheumatology (Oxford)
Russell MD, Ameyaw-Kyeremeh L, Dell'Accio F, Lapham H, Head N, Stovin C, Patel V, Clarke BD, Nagra D, Alveyn E, Adas MA, Bechman K, de la Puente MA, Ellis B, Byrne C, Patel R, Rutherford AI, Cantle F, Norton S, Roddy E, Hudson J, Cope AP, Galloway JB.   +22 more
europepmc   +1 more source

Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study. [PDF]

Rheumatology (Oxford)
Uhlig T, Karoliussen LF, Sexton J, Provan SA, Haavardsholm EA, Dalbeth N, Hammer HB.   +6 more
europepmc   +1 more source

Quantitative Assessment of Baseline Serum HDL-C to Predict Gout Flares During Urate-Lowering Therapy Initiation: A Prospective Cohort Study. [PDF]

J Inflamm Res
Jiang C, Li M, Chen Y, He Y, Li X, Cui L, Qi H, Cheng Z, Zhang X, Li C, Lu J.   +10 more
europepmc   +1 more source

Correction to "Gout Remission With Pegloticase-Induced Intensive Urate-Lowering Therapy: A Post Hoc Clinical Trial Analysis". [PDF]

ACR Open Rheumatol
europepmc   +1 more source

Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators. [PDF]

Sci Rep
Sanchez C, Campeau A, Liu-Bryan R, Mikuls TR, O'Dell JR, Gonzalez DJ, Terkeltaub R.   +6 more
europepmc   +1 more source

Urate-lowering therapy is associated with a reduced risk of arrhythmias: a systematic review and meta-analysis. [PDF]

J Rheum Dis
Waitayangkoon P, Leesutipornchai T, Techasatian W, Aiumtrakul N, Tanariyakul M, Arayangkool C, Kanthajan T, Nagamine T, Kewcharoen J.   +8 more
europepmc   +1 more source

Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout. [PDF]

Arthritis Rheumatol
Helget LN, O'Dell JR, Newcomb JA, Androsenko M, Brophy MT, Davis-Karim A, England BR, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, Wu H, Kramer B, Mikuls TR.   +13 more
europepmc   +1 more source

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation. [PDF]

Arthritis Res Ther
Holladay EE, Mudano AS, Xie F, Zhang J, Mikuls TR, LaMoreaux B, Padnick-Silver L, Curtis JR.   +7 more
europepmc   +1 more source

Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. [PDF]

Ann Rheum Dis
Tedeschi SK, Hayashi K, Zhang Y, Choi H, Solomon DH.   +4 more
europepmc   +1 more source

Erratum: Quantitative Assessment of Baseline Serum HDL-C to Predict Gout Flares During Urate-Lowering Therapy Initiation: A Prospective Cohort Study [Corrigendum]. [PDF]

J Inflamm Res
europepmc   +1 more source